Antitumor effect of polysaccharide TC-13 on allogeneic and syngeneic tumors in mice.

Abstract

The antitumor activity of TC-13, a protein-bound polysaccharide extracted from a rare actinomycetes was tested on allogeneic and syngeneic tumors in mice. In the allogeneic Ehrlich carcinoma system, TC-13 showed antitumor activity over a broad optimal dose range, when administered by various routes such as ip, iv, sc, it (intratumorally) or po, even when given before tumor inoculation. TC-13 showed synergistic antitumor effects in combination with other immunomodulators, e.g., lipopolysaccharide, lentinan and picibanil. It showed antitumor activity against syngeneic tumors, MM46 mammary carcinoma and MCS-8 and Meth A fibrosarcoma.

• Authors: M Kohno, S Abe, M Yamazaki, D Mizuno
• Journal: Gan (Gan) Vol. 73 Issue 3 Pg. 488-94 (Jun 1982) ISSN: 0016-450X [Print] Japan
• PMID: 7129013 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Antibiotics, Antineoplastic
• Glycopeptides
• Glycoproteins
• TC 13

Topics

• Animals
• Anti-Bacterial Agents
• Antibiotics, Antineoplastic (therapeutic use)
• Carcinoma, Ehrlich Tumor (drug therapy)
• Drug Evaluation, Preclinical
• Fibrosarcoma (drug therapy)
• Glycopeptides
• Glycoproteins (therapeutic use)
• Mammary Neoplasms, Experimental (drug therapy)
• Mice
• Mice, Inbred BALB C
• Mice, Inbred Strains
• Neoplasms, Experimental (drug therapy)
• Sarcoma, Experimental (drug therapy)
• Structure-Activity Relationship